Author

L. Torrente

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Assay:imaging· 1 Assay:metabolomics· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

G. M. DeNicola· 3 shared A. Falzone· 2 shared A. Huebner· 1 shared A. Jackson· 1 shared A. R. Barber· 1 shared A. T. Dinkova-Kostova· 1 shared C. C. Dibble· 1 shared C. Swanton· 1 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

G. M. DeNicola

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Imaging the master regulator of the antioxidant response in non-small cell lung cancer with positron emission tomography

H. E. Greenwood, R. S. Edwards, W. E. Tyrrell, A. R. Barber, F. Baark, M. Tanc, E. Khalil, A. Falzone, N. P. Ward, J. M. DeBlasi, L. Torrente, D. R. Pearce, G. Firth, L. M. Smith, O. Vilhelmsson Timmermand, , T. H. Witney

This study uses PET imaging to assess NRF2 activation in NSCLC, showing [18F]FSPG as a marker of therapeutic resistance and a potential target for treatment.

bioRxiv · Dec 16, 2023Cancer Biology

Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone

L. Torrente, N. Prieto, A. Falzone, D. A. Boothman, E. B. Haura, G. M. DeNicola

This study shows that NRF2/KEAP1 mutations confer resistance to β-lapachone by enhancing ROS detoxification, and that inhibiting SOD1 or the thioredoxin system can overcome this resistance.

bioRxiv · Nov 25, 2019Cancer Biology

The kinase inhibitor AT9283 selectively kills colorectal cancer cells with hyperactive NRF2

L. Torrente, G. Maan, L. Casares, A. Jackson, T. Honda, G. Wells, E. Kulesskiy, J. Saarela, A. T. Dinkova-Kostova, L. de la Vega

The paper identifies AT9283 as a drug that selectively kills colorectal cancer cells with hyperactive NRF2, showing its potential as a therapeutic target.

bioRxiv · Oct 21, 2019 · PreprintCancer Biology

Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer

Y. P. Kang, L. Torrente, M. Liu, J. M. Asara, C. C. Dibble, G. M. DeNicola

The paper identifies CDO1 as a metabolic liability in NSCLC by showing its silencing promotes proliferation through cysteine metabolism disruption.

bioRxiv · Nov 1, 2018Cancer Biology